Report on the Company (the Company's Views on “Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns”)
Sumitomo Pharma Co.,Ltd. (a consolidated subsidiary of the filing company)
Amchepry (the product)
Publication by GCR of a report based on one-sided views and assertions
Related procedures
Legal action (to be taken as necessary)
Regulatory authorities (name not stated)
Company response
The Company conducted its own review. The product has undergone scientific and medical review and investigation by regulatory authorities.
The Company aims to obtain full approval at an early date by appropriately conducting the post-marketing approval condition evaluation study (Phase 4 study) in accordance with the approval conditions and continuing to accumulate evidence on the efficacy and safety of Amchepry (the product). It will also take appropriate action, including legal action as necessary.
The Company will continue to provide shareholders and investors with timely and appropriate disclosure.
| Item | Details |
|---|---|
| Event name | Report on the Company (the Company's Views on “Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns”) |
| Date of occurrence | 7 August 2026 (the date on which GCR published the report) |
| Date recognized / date notice received | 12 August 2026 (the date on which the Company confirmed publication of the report) |
| Subject Entity | Sumitomo Pharma Co.,Ltd. (a consolidated subsidiary of the filing company) |
| Target Locations / Products | Amchepry (the product) |
| Cause | Publication by GCR of a report based on one-sided views and assertions |
| Type of litigation or proceeding | Legal action (to be taken as necessary) |
| Court or authority | Regulatory authorities (name not stated) |
| Investigation structure | The Company conducted its own review. The product has undergone scientific and medical review and investigation by regulatory authorities. |
| Outlook | The Company aims to obtain full approval at an early date by appropriately conducting the post-marketing approval condition evaluation study (Phase 4 study) in accordance with the approval conditions and continuing to accumulate evidence on the efficacy and safety of Amchepry (the product). It will also take appropriate action, including legal action as necessary. |
| Planned follow-up disclosure | The Company will continue to provide shareholders and investors with timely and appropriate disclosure. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The GCR report is unacceptable because it is based on one-sided views and assertions, and because GCR holds short positions in the shares of the company concerned and therefore stands to profit if the share price declines. The company also stated that it would respond to prevent its own interests and those of its shareholders and investors from being harmed by inaccurate or misleading information.